Holli Dilks on Molecular Profiling

Video

In Partnership With:

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Clinical trial eligibility is often dependent on molecular status, but determining which patients should undergo molecular profiling and when can be challenging, said Dilks.

The National Comprehensive Cancer Network (NCCN) offers guideline that can help oncologists determine at which stage of disease patients should be profiled.

Reaching out to pharmaceutical partners to find out the eligibility criteria for patients to enroll can also help oncologists determine when molecular profiling is necessary.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD